Page 165 - 20211214_OHKF_Health_Finance_Research_Report_E (1)
P. 165

Box 4.6

                                    Defining “diabetes” and “prediabetes”



                                    What is “diabetes mellitus”?

                                    Diabetes mellitus (DM) is a chronic disease, which occurs when the pancreas
                                    does not produce enough hormone insulin, or when the body cannot
                                    effectively use the insulin it produces. This leads to an increased
                                    concentration of glucose in the blood, clinically referred to as
                                    hyperglycaemia. There are three major types of DM: Type 1 diabetes, Type 2
                                    diabetes, and gestational diabetes. Type 2 diabetes is the most
                                    prevalent form of diabetes amongst Hong Kong adults.


                                    What is “prediabetes”?
                                    Prediabetes is a largely asymptomatic condition in patients at risk of
                                    progressing to a diagnosis of diabetes if the condition is not detected and
                                    addressed in a timely manner. It is characterised by blood sugar level that is
                                    higher than normal but not within the diabetic range, clinically
                                    referred to as intermediate hyperglycaemia. Individuals that fall within the
                                    prediabetic range can either have impaired fasting glucose or
                                    impaired glucose tolerance.




                             In 2003, the World Health Organization (WHO) and International Diabetes Federation (IDF)
                             met to propose screening as a possible solution to the growing burden of DM globally, with
                             projections at the time showing that DM prevalence will double to 350 million people
                             between the years 2003 and 2030 (WHO, 2003). This estimated prevalence was surpassed
                             in 2014, when the global burden of DM nearly quadrupled with an estimated 422
                             millions adults living with DM compared to 108 millions in 1980, with the
                             highest DM prevalence observed in China.

                             As a conclusion, in 2003, the two organisations drew a case for DM screening in countries
                             with increasing prevalence, outlining the considerations relevant to the development of a
                             screening policy (Figure 4.6). In cases, such as Hong Kong’s health system, where there is
                             capacity to screen and where prevalence of chronic conditions is growing, there is a strong
                             argument towards strengthening the screening capacity of the health system.




























                                                                                                               163
   160   161   162   163   164   165   166   167   168   169   170